SCHEMBL1697377

SCHEMBL1697377

NC(CO)C(=O)NCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 2/20 0.53
KMT2A Q03164 1/20 0.53
EGFR P00533 2/20 0.52
SRC P12931 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
TSHR P16473 1/20 0.51
CYP2C19 P33261 1/20 0.51
SLC1A1 P43005 1/20 0.49
MME P08473 1/20 0.49
MMP2 P08253 1/20 0.49
GAA P10253 1/20 0.49
FNTA P49354 1/20 0.48
FNTB P49356 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA3 P07451 1/20 0.48
CA4 P22748 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653978 1.00 MMP8 (0.53) MMP8KMT2AEGFRSRCCYP1A2
SCHEMBL47278 1.00 MMP8 (0.53) MMP8KMT2AEGFRSRCCYP1A2
SCHEMBL18952189 0.86 SPHK1 (0.62) MMP8KMT2AEGFRSRCCYP1A2
SCHEMBL7413310 0.86 ALPI (0.61) MMP8KMT2AEGFRSRCMME
SCHEMBL3114367 0.86 ALPI (0.61) MMP8KMT2AEGFRSRCMME
SCHEMBL12240253 0.84 KMT2A (0.55) MMP8KMT2AEGFRSRCMME
SCHEMBL2742291 0.84 KMT2A (0.55) MMP8KMT2AEGFRSRCMME
SCHEMBL20569813 0.84 TPSAB1 (0.58) CYP1A2CYP2D6CYP2C9TSHRCYP2C19
SCHEMBL16289699 0.84 MMP2 (0.68) MMP8KMT2AEGFRSRCCYP1A2
Hydrochloric Acid SCHEMBL3385081 0.84 MMP8 (0.59) MMP8KMT2AEGFRSRCMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106866453-B A kind of method that microreactor prepares scheme for lacosamide 齐鲁天和惠世制药有限公司 2019-03-22 CN claimed
US-8829226-B2 Lacosamide intermediate compound, preparation method thereof and use thereof ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD (CN) 2014-09-09 US claimed
CN-102146048-B Lacosamide intermediate compound and preparation method and application thereof ZHEJIANG JIUZHOU PHARM CO LTD 2013-11-13 CN claimed
US-20130066102-A1 LACOSAMIDE INTERMEDIATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD (CN) 2013-03-14 US claimed
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES PRIVATE LIMITED (IN) 2013-02-14 US claimed
EP-2534127-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN Laboratories Limited (IN) 2012-12-19 EP claimed
US-20120283466-A1 LACOSAMIDE INTERMEDIATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2012-11-08 US claimed
WO-2011099033-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES LIMITED (IN) 2011-08-18 WO claimed
CN-102146048-A Lacosamide intermediate compound and preparation method and application thereof ZHEJIANG JIUZHOU PHARM CO LTD 2011-08-10 CN claimed
EP-3519382-B1 AN IMPROVED PROCESS FOR THE PREPARATION OF LACOSAMIDE UNICHEM LAB LTD (IN) 2021-10-27 EP disclosed
CN-111269140-A Preparation method of lacosamide 上海奥博生物医药技术有限公司 2020-06-12 CN disclosed
WO-2018060781-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF LACOSAMIDE UNICHEM LABORATORIES LTD (IN) 2018-04-05 WO disclosed
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP disclosed
CN-106543018-A The method for preparing scheme for lacosamide 迪比斯实验股份有限公司 2017-03-29 CN disclosed
EP-1038522-A2 Anticonvulsant enantiomeric amino acid derivatives Research Corporation Technologies, Inc (US) 2000-09-27 EP disclosed
EP-0996435-A1 AMINO ACID DERIVATIVES USEFUL TO TREAT STROKE Research Corporation Technologies, Inc (US) 2000-05-03 EP disclosed
WO-1999003460-A1 AMINO ACID DERIVATIVES USEFUL TO TREAT STROKE RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1999-01-28 WO disclosed
EP-0888289-A1 ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES Research Corporation Technologies, Inc (US) 1999-01-07 EP disclosed
US-5773475-A DIPEPTIDES FOR CENTRAL NERVOUS SYSTEM DISORDERS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1998-06-30 US disclosed
WO-1997033861-A1 ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1997-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130066102-A1 LACOSAMIDE INTERMEDIATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF IDH3A, CACNA1C, DDC MMP8 778/4885KMT2A 723/4885EGFR 2617/4885
US-20120283466-A1 LACOSAMIDE INTERMEDIATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF IDH3A, CACNA1C, DDC MMP8 778/4885KMT2A 723/4885EGFR 2617/4885
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE AMY1A, PTMA, NAAA MMP8 4364/4885KMT2A 1675/4885EGFR 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.